• Explore /
  • Poster
  • / Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.

Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.

Abstract Video & Slides Poster

Authors

null

Salomon Manier

Centre Hospitalier Regional Universitaire de Lille, Lille, France

Salomon Manier , Ankit J. Kansagra , Larry D. Anderson, Jr , Jesus G. Berdeja , Sundar Jagannath , Yi Lin , Sagar Lonial , Nina Shah , Noopur S. Raje , David Samuel DiCapua Siegel , Albert Oriol , Anna Truppel-Hartmann , Everton Rowe , Payal Patel , Amit Agarwal , Timothy B. Campbell , Paula Rodríguez-Otero , Nikhil C. Munshi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03361748

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 8036)

DOI

10.1200/JCO.2021.39.15_suppl.8036

Abstract #

8036

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Julia Piasecki

First Author: Larry D. Anderson, Jr

First Author: Nicholas Stong

First Author: Ross Firestone